Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ischemic Heart Disease

  Free Subscription


Articles published in JAMA

Retrieve available abstracts of 87 articles:
HTML format
Text format



Single Articles


    March 2017
  1. KHERA AV, Won HH, Peloso GM, O'Dushlaine C, et al
    Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease.
    JAMA. 2017;317:937-946.
    PubMed     Text format     Abstract available


    February 2017
  2. BUDOFF MJ, Ellenberg SS, Lewis CE, Mohler ER 3rd, et al
    Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone.
    JAMA. 2017;317:708-716.
    PubMed     Text format     Abstract available


  3. AGORITSAS T, Merglen A, Shah ND, O'Donnell M, et al
    Adjusted Analyses in Studies Addressing Therapy and Harm: Users' Guides to the Medical Literature.
    JAMA. 2017;317:748-759.
    PubMed     Text format     Abstract available


  4. BILECEN S, de Groot JA, Kalkman CJ, Spanjersberg AJ, et al
    Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial.
    JAMA. 2017;317:738-747.
    PubMed     Text format     Abstract available


  5. EMDIN CA, Khera AV, Natarajan P, Klarin D, et al
    Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease.
    JAMA. 2017;317:626-634.
    PubMed     Text format     Abstract available


    January 2017
  6. SILVERMAN MG, Im K, Sabatine MS
    Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk-Reply.
    JAMA. 2017;317:440.
    PubMed     Text format    


  7. ZAFAR K, Inayat M
    Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk.
    JAMA. 2017;317:439-440.
    PubMed     Text format    


  8. NAVARESE EP, Kolodziejczak M, De Servi S
    Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk.
    JAMA. 2017;317:439.
    PubMed     Text format    


  9. BRAGG F, Holmes MV, Iona A, Guo Y, et al
    Association Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of China.
    JAMA. 2017;317:280-289.
    PubMed     Text format     Abstract available


  10. GREENWOOD JP, Brown JM, Berry C
    Alternatives in the Evaluation of Suspected Coronary Heart Disease-Reply.
    JAMA. 2017;317:212-213.
    PubMed     Text format    


  11. SCHWITTER J
    Alternatives in the Evaluation of Suspected Coronary Heart Disease.
    JAMA. 2017;317:211-212.
    PubMed     Text format    


  12. BITTENCOURT MS, Fernandes JL
    Alternatives in the Evaluation of Suspected Coronary Heart Disease.
    JAMA. 2017;317:211.
    PubMed     Text format    


  13. FOROUZANFAR MH, Liu P, Roth GA, Ng M, et al
    Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015.
    JAMA. 2017;317:165-182.
    PubMed     Text format     Abstract available


    December 2016
  14. SLOMSKI A
    Celecoxib Similar to 2 NSAIDs for Cardiovascular Safety.
    JAMA. 2016;316:2589.
    PubMed     Text format    


  15. DESAI NR, Ross JS, Kwon JY, Herrin J, et al
    Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions.
    JAMA. 2016;316:2647-2656.
    PubMed     Text format     Abstract available


  16. MORA S, Manson JE
    Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Disease-Reply.
    JAMA. 2016;316:2276-2277.
    PubMed     Text format    


  17. STOVITZ SD, Satin DJ, Shrier I
    Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Disease.
    JAMA. 2016;316:2276.
    PubMed     Text format    


    November 2016
  18. NICHOLLS SJ, Puri R, Anderson T, Ballantyne CM, et al
    Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    JAMA. 2016 Nov 15. doi: 10.1001/jama.2016.16951.
    PubMed     Text format     Abstract available


  19. NAVAR AM, Peterson ED, Wojdyla D, Sanchez RJ, et al
    Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence.
    JAMA. 2016;316:2041-2043.
    PubMed     Text format    


  20. KAVOUSI M, Desai CS, Ayers C, Blumenthal RS, et al
    Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women: A Meta-analysis.
    JAMA. 2016 Nov 15. doi: 10.1001/jama.2016.17020.
    PubMed     Text format     Abstract available


  21. RODRIGUEZ F, Harrington RA
    Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering.
    JAMA. 2016;316:1967-1968.
    PubMed     Text format    


  22. BIBBINS-DOMINGO K, Grossman DC, Curry SJ, Davidson KW, et al
    Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2016;316:1997-2007.
    PubMed     Text format     Abstract available


  23. CHOU R, Dana T, Blazina I, Daeges M, et al
    Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2016;316:2008-2024.
    PubMed     Text format     Abstract available


  24. SONG Z, Blumenthal DM
    Expanding Payment Reform in Medicare: The Cardiology Episode-Based Payment Model.
    JAMA. 2016;316:1973-1974.
    PubMed     Text format    


  25. ABBASI J
    Do Apollo Astronaut Deaths Shine a Light on Deep Space Radiation and Cardiovascular Disease?
    JAMA. 2016 Nov 9. doi: 10.1001/jama.2016.12601.
    PubMed     Text format    


  26. LEGATO MJ, Johnson PA, Manson JE
    Consideration of Sex Differences in Medicine to Improve Health Care and Patient Outcomes.
    JAMA. 2016;316:1865-1866.
    PubMed     Text format    


    October 2016
  27. HAMPTON T
    Reservoir of Genetic Data Related to Cardiovascular Disease.
    JAMA. 2016;316:1349.
    PubMed     Text format    


  28. LOTTA LA, Sharp SJ, Burgess S, Perry JR, et al
    Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
    JAMA. 2016;316:1383-1391.
    PubMed     Text format     Abstract available


    September 2016
  29. SILVERMAN MG, Ference BA, Im K, Wiviott SD, et al
    Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
    JAMA. 2016;316:1289-97.
    PubMed     Text format     Abstract available


  30. MILLS K, He J
    Sodium Excretion, Cardiovascular Disease, and Chronic Kidney Disease.
    JAMA. 2016;316:1112-3.
    PubMed     Text format    


  31. ALMIRALL J
    Sodium Excretion, Cardiovascular Disease, and Chronic Kidney Disease.
    JAMA. 2016;316:1112.
    PubMed     Text format    


  32. HURSITOGLU M
    Sodium Excretion, Cardiovascular Disease, and Chronic Kidney Disease.
    JAMA. 2016;316:1112.
    PubMed     Text format    


  33. HEMKENS LG, Ewald H, Briel M
    Colchicine and Prevention of Cardiovascular Events.
    JAMA. 2016;316:1106-7.
    PubMed     Text format     Abstract available


    August 2016
  34. HALL M, Dondo TB, Yan AT, Goodman SG, et al
    Association of Clinical Factors and Therapeutic Strategies With Improvements in Survival Following Non-ST-Elevation Myocardial Infarction, 2003-2013.
    JAMA. 2016 Aug 30. doi: 10.1001/jama.2016.10766.
    PubMed     Text format     Abstract available


  35. BOHULA EA, Antman EM
    Management of Non-ST-Elevation Myocardial Infarction: The Bright Gleam of Progress, But Much Work Remains.
    JAMA. 2016 Aug 30. doi: 10.1001/jama.2016.11940.
    PubMed     Text format    


  36. GREENWOOD JP, Ripley DP, Berry C, McCann GP, et al
    Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates: The CE-MARC 2 Randomized Clinical Trial.
    JAMA. 2016 Aug 29. doi: 10.1001/jama.2016.12680.
    PubMed     Text format     Abstract available


  37. KAZI DS, Moran AE, Coxson PG, Penko J, et al
    Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    JAMA. 2016;316:743-53.
    PubMed     Text format     Abstract available


  38. LIVINGSTON EH
    JAMA PATIENT PAGE. Screening for Lipid Disorders in Children and Adolescents.
    JAMA. 2016;316:678.
    PubMed     Text format    


  39. LOZANO P, Henrikson NB, Dunn J, Morrison CC, et al
    Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2016;316:645-55.
    PubMed     Text format     Abstract available


  40. LOZANO P, Henrikson NB, Morrison CC, Dunn J, et al
    Lipid Screening in Childhood and Adolescence for Detection of Multifactorial Dyslipidemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2016;316:634-44.
    PubMed     Text format     Abstract available


    July 2016
  41. NUTI SV, Qin L, Krumholz HM
    Outcome After Admission at Veterans Affairs vs Non-Veterans Affairs Hospitals--Reply.
    JAMA. 2016;316:346.
    PubMed     Text format    


  42. RADOMSKI TR, Fine MJ, Gellad WF
    Outcome After Admission at Veterans Affairs vs Non-Veterans Affairs Hospitals.
    JAMA. 2016;316:345-6.
    PubMed     Text format    


    June 2016
  43. CHOBANIAN AV
    SPRINT Results in Older Patients: How Low to Go?
    JAMA. 2016;315:2669-70.
    PubMed     Text format    


  44. GANZ P, Heidecker B, Hveem K, Jonasson C, et al
    Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease.
    JAMA. 2016;315:2532-41.
    PubMed     Text format     Abstract available


  45. SABATINE MS
    Using Aptamer-Based Technology to Probe the Plasma Proteome for Cardiovascular Disease Prediction.
    JAMA. 2016;315:2525-6.
    PubMed     Text format    


  46. MORA S, Ames JM, Manson JE
    Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease: Shared Decision Making in Clinical Practice.
    JAMA. 2016 Jun 20. doi: 10.1001/jama.2016.8362.
    PubMed     Text format    


  47. HONG SJ, Kim BK, Hong MK
    Ultrasound vs Angiography for Drug-Eluting Stent Implantation--Reply.
    JAMA. 2016;315:2469-70.
    PubMed     Text format    


  48. STEINVIL A, Waksman R, Garcia-Garcia HM
    Ultrasound vs Angiography for Drug-Eluting Stent Implantation.
    JAMA. 2016;315:2469.
    PubMed     Text format    


  49. TUNCEZ A, Altunkeser BB
    Ultrasound vs Angiography for Drug-Eluting Stent Implantation.
    JAMA. 2016;315:2468-9.
    PubMed     Text format    


  50. HOFFER EK
    Ultrasound vs Angiography for Drug-Eluting Stent Implantation.
    JAMA. 2016;315:2468.
    PubMed     Text format    


  51. MANSON JE, Shufelt CL, Robins JM
    The Potential for Postrandomization Confounding in Randomized Clinical Trials.
    JAMA. 2016;315:2273-4.
    PubMed     Text format    


    May 2016
  52. MILLS KT, Chen J, Yang W, Appel LJ, et al
    Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease.
    JAMA. 2016;315:2200-10.
    PubMed     Text format     Abstract available


  53. POWE NR, Bibbins-Domingo K
    Dietary Salt, Kidney Disease, and Cardiovascular Health.
    JAMA. 2016;315:2173-4.
    PubMed     Text format    


  54. WILLIAMSON JD, Supiano MA, Applegate WB, Berlowitz DR, et al
    Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >/=75 Years: A Randomized Clinical Trial.
    JAMA. 2016 May 19. doi: 10.1001/jama.2016.7050.
    PubMed     Text format     Abstract available


  55. POLONSKY TS, Blankstein R
    Treatment of Patients With Stable Ischemic Heart Disease--Reply.
    JAMA. 2016;315:1906-7.
    PubMed     Text format    


  56. BANGALORE S, Maron DJ, Hochman JS
    Treatment of Patients With Stable Ischemic Heart Disease--Reply.
    JAMA. 2016;315:1905-6.
    PubMed     Text format    


  57. LADAPO JA
    Treatment of Patients With Stable Ischemic Heart Disease.
    JAMA. 2016;315:1905.
    PubMed     Text format    


  58. CIVEIRA F, Mateo-Gallego R
    Treatment of Patients With Stable Ischemic Heart Disease.
    JAMA. 2016;315:1904-5.
    PubMed     Text format    


    April 2016
  59. VETTER C, Devore EE, Wegrzyn LR, Massa J, et al
    Association Between Rotating Night Shift Work and Risk of Coronary Heart Disease Among Women.
    JAMA. 2016;315:1726-34.
    PubMed     Text format     Abstract available


  60. PENCINA MJ, Peterson ED
    Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling.
    JAMA. 2016;315:1713-4.
    PubMed     Text format    


  61. EIJSVOGELS TM, Thompson PD
    Exercise Intensity, Dose, and Cardiovascular Disease--Reply.
    JAMA. 2016;315:1659.
    PubMed     Text format    


  62. SANCHIS-GOMAR F, Fiuza-Luces C, Lucia A
    Exercise Intensity, Dose, and Cardiovascular Disease.
    JAMA. 2016;315:1658-9.
    PubMed     Text format    


  63. GHAHRAMANI GK, Seline AE, Wanat KA
    Postprocedural Blue Toes.
    JAMA. 2016;315:1396-7.
    PubMed     Text format    


  64. O'DONOGHUE ML, Glaser R, Cavender MA, Aylward PE, et al
    Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
    JAMA. 2016 Apr 4. doi: 10.1001/jama.2016.3609.
    PubMed     Text format     Abstract available


    March 2016
  65. YEH RW, Secemsky EA, Kereiakes DJ, Normand ST, et al
    Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
    JAMA. 2016 Mar 29. doi: 10.1001/jama.2016.3775.
    PubMed     Text format     Abstract available


  66. LEENING MJ, Berry JD, Allen NB
    Lifetime Perspectives on Primary Prevention of Atherosclerotic Cardiovascular Disease.
    JAMA. 2016 Mar 21. doi: 10.1001/jama.2016.1654.
    PubMed     Text format    


  67. THAKKAR J, Redfern J, Chow CK
    Targeted Text Messaging Support for Patients With Coronary Heart Disease--Reply.
    JAMA. 2016;315:1056-7.
    PubMed     Text format    


  68. KAMARCK T
    Targeted Text Messaging Support for Patients With Coronary Heart Disease.
    JAMA. 2016;315:1056.
    PubMed     Text format    


  69. NISSEN SE, Wolski KE, Prcela L, Wadden T, et al
    Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
    JAMA. 2016;315:990-1004.
    PubMed     Text format     Abstract available


  70. SHARFSTEIN JM, Psaty BM
    Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A Study Interrupted.
    JAMA. 2016;315:984-6.
    PubMed     Text format    


    February 2016
  71. PUTMAN RK, Hatabu H, Araki T, Gudmundsson G, et al
    Association Between Interstitial Lung Abnormalities and All-Cause Mortality.
    JAMA. 2016;315:672-81.
    PubMed     Text format     Abstract available


  72. NUTI SV, Qin L, Rumsfeld JS, Ross JS, et al
    Association of Admission to Veterans Affairs Hospitals vs Non-Veterans Affairs Hospitals With Mortality and Readmission Rates Among Older Men Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia.
    JAMA. 2016;315:582-92.
    PubMed     Text format     Abstract available


  73. JHA AK
    Learning From the Past to Improve VA Health Care.
    JAMA. 2016;315:560-1.
    PubMed     Text format    


    December 2015
  74. SANGHAVI DM, Conway PH
    Approaches to Prevention of Cardiovascular Disease--Reply.
    JAMA. 2015;314:2306-7.
    PubMed     Text format    


  75. FEIGIN VL, Norrving B, Wiebers DO
    Approaches to Prevention of Cardiovascular Disease.
    JAMA. 2015;314:2306.
    PubMed     Text format    


    November 2015
  76. PURSNANI A, Massaro JM, Hoffmann U
    Predicted vs Observed Clinical Event Risk for Cardiovascular Disease-Reply.
    JAMA. 2015;314:2082-2083.
    PubMed     Text format    


  77. DEFILIPPIS AP, Blaha MJ
    Predicted vs Observed Clinical Event Risk for Cardiovascular Disease.
    JAMA. 2015;314:2082.
    PubMed     Text format    


  78. BANGALORE S, Maron DJ, Hochman JS
    Evidence-Based Management of Stable Ischemic Heart Disease: Challenges and Confusion.
    JAMA. 2015;314:1917-8.
    PubMed     Text format    


  79. FANAROFF AC, Rymer JA, Goldstein SA
    JAMA Patient Page. Acute Coronary Syndrome.
    JAMA. 2015;314:1990.
    PubMed     Text format    


  80. OSLER W
    Angina Pectoris and Arteriosclerosis.
    JAMA. 2015;314:1981.
    PubMed     Text format    


  81. FANAROFF AC, Rymer JA, Goldstein SA, Simel DL, et al
    Does This Patient With Chest Pain Have Acute Coronary Syndrome?: The Rational Clinical Examination Systematic Review.
    JAMA. 2015;314:1955-65.
    PubMed     Text format     Abstract available


  82. GAZIANO JM, Peterson ED, Greenland P
    Advancing Cardiovascular Science.
    JAMA. 2015;314:1924-5.
    PubMed     Text format    


  83. DESAI NR, Bradley SM, Parzynski CS, Nallamothu BK, et al
    Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention.
    JAMA. 2015 Nov 9:2045-2053. doi: 10.1001/jama.2015.13764.
    PubMed     Text format     Abstract available


  84. HARRINGTON RA
    Appropriate Use Criteria for Coronary Revascularization and the Learning Health System: A Good Start.
    JAMA. 2015 Nov 9:1-3. doi: 10.1001/jama.2015.15436.
    PubMed     Text format    


  85. SVATIKOVA A, Covassin N, Somers KR, Somers KV, et al
    A Randomized Trial of Cardiovascular Responses to Energy Drink Consumption in Healthy Adults.
    JAMA. 2015 Nov 8:1-3. doi: 10.1001/jama.2015.13744.
    PubMed     Text format    


  86. POKORNEY SD, Peterson ED, Wang TY
    Use of Implantable Cardioverter-Defibrillators Among Medicare Patients--Reply.
    JAMA. 2015;314:1874-5.
    PubMed     Text format    


  87. FORMAN DE, Maurer MS, Rich MW
    Use of Implantable Cardioverter-Defibrillators Among Medicare Patients.
    JAMA. 2015;314:1873-4.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: